Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Alpa Laboratories, incorporated is engaged in the business of manufacturing pharmaceutical products.The company manufactures a spectrum of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products. These products are manufactured in various dosage forms such as injectables (vials/ampoules both liquid and dry), tablets, capsules, eye/ear drops, ointment and creams. The company markets these products under the trademark `Alpa`.The company manufactures formulations for other major pharmaceutical companies namely Cipla, Zydus Cadila, Lupin, Glenmark, Genom, Biotech Jenburkt etc. Alpa Laboratories exports a wide range of products to countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka, etc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Indore, Madhya Pradesh
- Chairman
- Mahendra Singh Chawla
- CEO & MD
- Paresh Chawla
- Registrar
- Bigshare Services Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE385I01010
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Alpa Laboratories Ltd today?
Alpa Laboratories Ltd (ALPA) is trading at ₹49.29. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is ALPA’s P/E ratio versus the sector?
ALPA trades at a P/E of 27.2. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is ALPA’s dividend yield?
ALPA has a dividend yield of 0.00%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is ALPA’s 52-week high and low?
ALPA has traded between ₹46.1 and ₹93.85 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Alpa Laboratories Ltd?
Alpa Laboratories Ltd has a market capitalisation of ₹119 crore.
▶What is ALPA’s return on equity?
ALPA reports a return on equity of 7.9%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are ALPA’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is ALPA’s promoter holding?
Promoters hold 57.19% of ALPA. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include ALPA?
Index membership is listed in the Context block on this page, along with the weight ALPA carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Alpa Laboratories Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from ALPA’s own numbers. The judgement is yours.
ALPA at a glance
Alpa Laboratories Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Alpa Laboratories Ltd (ALPA) last traded at ₹49.29, giving it a market capitalisation of ₹119 crore. The 52-week range is ₹46.1 to ₹93.85, and the price is 7% of the way up that range. It trades at a price-to-earnings ratio of 27.2. Promoters hold 57.19% of the company in the latest shareholding filing.
| Market cap | ₹119 crore |
|---|---|
| P/E | 27.2 |
| ROE | 7.9% |
| ROCE | 8.9% |